Market revenue in 2023 | USD 3,026.4 million |
Market revenue in 2030 | USD 5,620.2 million |
Growth rate | 9.2% (CAGR from 2023 to 2030) |
Largest segment | Ferric carboxymaltose |
Fastest growing segment | Ferric Carboxymaltose |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Iron Dextran, Iron Sucrose, Ferric Carboxymaltose |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intravenous iron drugs market will help companies and investors design strategic landscapes.
ferric carboxymaltose was the largest segment with a revenue share of 50.22% in 2023. Horizon Databook has segmented the Global intravenous iron drugs market based on iron dextran, iron sucrose, ferric carboxymaltose covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of global-level data and insights on the Global intravenous iron drugs market , including forecasts for subscribers. This global databook contains high-level insights into Global intravenous iron drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account